Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?

Oncotarget

Volumn 3, Issue 11, 2012, Pages 1335-1347

  Caraux, Anouk ^a   Vincent, Laure ^a,b   Bouhya, Salahedine ^b   Quittet, Philippe ^b   Moreaux, Jérôme ^b   Requirand, Guilhem ^b   Veyrune, Jean Luc ^b   Olivier, Gaëlle ^b   Cartron, Guillaume ^b   Rossi, Jean François ^b   Klein, Bernard ^a,b,c  

^a INSERM   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Human; Minimal residual disease; Multiple myeloma; Plasma cells

Indexed keywords

B CELL ACTIVATING FACTOR; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELPHALAN; RANTES; VASCULOTROPIN;

ADULT; AGED; APLASIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CELL; CANCER DIAGNOSIS; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMA CELL;

EID: 84872794840     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.650     Document Type: Article

References (40)

1. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011; 183:25-35.
2. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011; 2011:26.
3. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010; 376(9758):2075-2085.
4. Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A, Vidriales MB, Lopez-Berges MC, Miguel JF and Orfao A. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom. 2010; 78(4):239-252.
5. Domingo E, Moreno C, Sanchez-Ibarrola A, Panizo C, Paramo JA and Merino J. Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease. Haematologica. 2010; 95(4):691-692.
6. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, Garcia de Coca A, de Las Heras N, Mateos MV, Lopez- Berges MC, Garcia-Boyero R, Galende J, Hernandez J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008; 112(10):4017-4023.
7. Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, Alonso L, Oriol A, Teruel AI, de Paz R, Larana JG, Bengoechea E, Martin A, Mediavilla JD, Palomera L, de Arriba F, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011; 29(12):1627-1633.
8. Mahtouk K, Hose D, De Vos J, Moreaux J, Jourdan M, Rossi JF, Reme T, Goldschmidt H and Klein B. Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications. Clin Cancer Res. 2007; 13(24):7289-7295.
9. Gu ZJ, Vos JD, Rebouissou C, Jourdan M, Zhang XG, Rossi JF, Wijdenes J and Klein B. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia. 2000; 14(1):188-197.
10. Hideshima T, Mitsiades C, Tonon G, Richardson PG and Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007; 7(8):585-598.
11. Klein B, Seckinger A, Moehler T and Hose D. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. Recent Results Cancer Res. 2011; 183:39-86.
12. Podar K, Chauhan D and Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009; 23(1):10-24.
13. Ria R, Todoerti K, Berardi S, Coluccia AM, De Luisi A, Mattioli M, Ronchetti D, Morabito F, Guarini A, Petrucci MT, Dammacco F, Ribatti D, Neri A and Vacca A. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res. 2009; 15(17):5369-5378.
14. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Reme T and Bourin P. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007; 21(5):1079-1088.
15. Minges Wols HA, Underhill GH, Kansas GS and Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol. 2002; 169(8):4213-4221.
16. Tokoyoda K, Egawa T, Sugiyama T, Choi BI and Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity. 2004; 20(6):707-718.
17. Giuliani N and Rizzoli V. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma. 2007; 48(12):2323-2329.
18. Andersen TL, Soe K, Sondergaard TE, Plesner T and Delaisse JM. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J Haematol. 2010; 148(4):551-561.
19. Moreaux J, Hose D, Kassambara A, Reme T, Moine P, Requirand G, Goldschmidt H and Klein B. Osteoclastgene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. Blood. 2011; 117(4):1280-1290.
20. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B and Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004; 64(6):2016-2023.
21. Matthes T, Dunand-Sauthier I, Santiago-Raber ML, Krause KH, Donze O, Passweg J, McKee T and Huard B. Production of the plasma-cell survival factor a proliferationinducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood. 2011; 118(7):1838-1844.
22. Winter O, Moser K, Mohr E, Zotos D, Kaminski H, Szyska M, Roth K, Wong DM, Dame C, Tarlinton DM, Schulze H, MacLennan IC and Manz RA. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood. 2010; 116(11):1867-1875.
23. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933):1457-1461.
24. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE and Singhal AK. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2011; 120(3):552-9.
25. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008; 14(9):2775-2784.
26. Van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD, Jr., et al. Combinatorial efficacy of anti- CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009; 8(9):2616-2624.
27. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Mohler T, De Vos J, Rossi JF, Goldschmidt H and Klein B. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006; 108(13):4194-4197.
28. Olteanu H, Harrington AM, Hari P and Kroft SH. CD200 expression in plasma cell myeloma. Br J Haematol. 2011; 153(3):408-411.
29. Vande Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B and Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer. 2003; 88(6):855-862.
30. Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, Dinant HJ, Lee Y, Wyant T, Jacobson EW, Baeten D and Tak PP. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2008; 58(7):1931-1939.
31. Rossi JF, Fegueux N, Lu ZY, Legouffe E, Exbrayat C, Bozonnat MC, Navarro R, Lopez E, Quittet P, Daures JP, Rouille V, Kanouni T, Widjenes J and Klein B. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant. 2005; 36(9):771-779.
32. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T and Hiepe F. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006; 6(10):741-750.
33. Mohr E, Serre K, Manz RA, Cunningham AF, Khan M, Hardie DL, Bird R and MacLennan ICM. Dendritic Cells and Monocyte/Macrophages That Create the IL-6/APRILRich Lymph Node Microenvironments Where Plasmablasts Mature. J Immunol. 2009; 182(4):2113-2123.
34. Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, Bos NA, Johnsen HE, Orfao A, Perez-Andres M and Myeloma Stem Cell N. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica. 2010; 95(6):1016-1020.
35. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, Muehlinghaus G, Berek C, Hiepe F, Manz R, Radbruch A and Dorner T. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood. 2005; 105(4):1614-1621.
36. Caraux A, Perez-Andres M, Larroque M, Requirand G, Lu ZY, Kanouni T, Rossi JF, Orfao A and Klein B. Mobilization of plasma cells in healthy individuals treated with granulocyte colony-stimulating factor for haematopoietic stem cell collection. Immunology. 2011; 132(2):266-272.
37. Paiva B, Perez-Andres M, Vidriales MB, Almeida J, de las Heras N, Mateos MV, Lopez-Corral L, Gutierrez NC, Blanco J, Oriol A, Hernandez MT, de Arriba F and de. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. 2011; 25(4):697-706.
38. Kyle RA and Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009; 23(1):3-9.
39. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348(26):2609-2617.
40. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omede P, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008; 93(3):431-438.